News

Bristol-Myers Squibb has reported the expiration of Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex. The expiration of the HSR waiting period satisfies one of the

Hana Biosciences (Hana) has achieved its enrollment goal of 56 evaluable subjects in the pivotal phase 2 rALLy clinical trial for Marqibo (vincristine sulfate liposomes injection). It is

Arrayit said that Arrayit Diagnostics Inc. will spearhead an intensive marketing campaign in an effort to establish Arrayit in the diagnostics sector.

Neurobiological Technologies (NTI) has entered into an agreement to terminate its license and cooperation agreement with Merz Pharmaceuticals (Merz) and Children’s Medical Center Corporation (CMCC). Pursuant to the

Ranbaxy has launched its protein supplement under the brand name, Revitalite, marking its entry into the protein supplements market in India. The company claims that Revitalite offers a

Capstone Therapeutics reported a net loss of $3.1m, or $0.08 per share, for the second quarter of 2009, compared to a net loss of $2.8m or $0.07 per

CytRx has reported that INNO-206 showed to inhibit tumor growth in an experimental animal model of small cell lung cancer (SCLC). INNO-206 is a pro-drug derivative of the

Palatin Technologies (Palatin) has completed phase 1 clinical trial of bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD).

AstraZeneca and Forest Laboratories (Forest) have sealed a collaboration agreement to co-develop and commercialise ceftaroline in all markets outside the US, Canada and Japan. Ceftaroline, Forest’s late stage